Profil
Daniel Harris Rosenbaum is currently the Chief Executive Officer at Kaydence Pharma USA. Prior to this, he was the Chief Executive Officer at NattoPharma ASA from 2015 to 2018.
He also worked as the General Manager-Nutraceuticals & Pharmaceutical at FMC Corp.
Mr. Rosenbaum completed his undergraduate degree at Cornell University and earned an MBA from Tuck School of Business at Dartmouth.
Aktive Positionen von Dan Rosenbaum
| Unternehmen | Position | Beginn |
|---|---|---|
Kaydence Pharma USA
Kaydence Pharma USA Pharmaceuticals: MajorHealth Technology Develops menaquinone-7 for the treatment of vascular and tissue calcification-related diseases | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Dan Rosenbaum
| Unternehmen | Position | Ende |
|---|---|---|
| NATTOPHARMA ASA | Vorstandsvorsitzender | 10.02.2018 |
| FMC CORPORATION | Corporate Officer/Principal | - |
Ausbildung von Dan Rosenbaum
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
FMC Corp.
FMC Corp. Chemicals: AgriculturalProcess Industries Operates as an agricultural sciences company which produces insecticides, herbicides and fungicides & crop nutrition and seed treatment products | Process Industries |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NattoPharma ASA
NattoPharma ASA Pharmaceuticals: MajorHealth Technology Manufactures, distributes, markets and sells vitamin K2 products | Health Technology |
Tuck School of Business at Dartmouth
Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kaydence Pharma USA
Kaydence Pharma USA Pharmaceuticals: MajorHealth Technology Develops menaquinone-7 for the treatment of vascular and tissue calcification-related diseases | Health Technology |
















